Compare RMNI & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMNI | CYPH |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 321.1M |
| IPO Year | 2015 | 2019 |
| Metric | RMNI | CYPH |
|---|---|---|
| Price | $4.83 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.17 | N/A |
| AVG Volume (30 Days) | 553.5K | ★ 12.7M |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 197.50 | 103.87 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $431,496,000.00 | $1,500,000.00 |
| Revenue This Year | $5.92 | N/A |
| Revenue Next Year | $5.90 | $590.88 |
| P/E Ratio | $47.73 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $2.87 | $0.49 |
| 52 Week High | $5.68 | $4.19 |
| Indicator | RMNI | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 33.85 |
| Support Level | $4.02 | $0.65 |
| Resistance Level | $5.01 | $3.42 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 23.38 | 4.44 |
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.